Latest Tokyo Brief coverage on Shionogi & Co.,Ltd., tracking filings, financial news, and market signals from Japan.
TSE:4507
Shionogi and Torii Pharmaceutical secured Japanese approval to prescribe a 0.5% version of their non-steroid eczema cream to children under 12, backed by a trial in patients aged 2 to under 12 showing it beat plain vehicle cream over eight weeks with good long-term tolerability.
Shionogi cleared a Japanese approval adding a booster dose to its Omicron JN.1 COVID-19 vaccine, completing the technical groundwork for supplying future season-matched shots, but the approved formulation itself won't be sold because it doesn't match the strain designated for the 2026-2027 season.
A string of drugmaker acquisitions, not stronger underlying sales, pushed Shionogi's quarterly net profit up 148% to ¥97.7bn, covering most of its own first-half profit guidance within three months while cutting its cash pile by more than half.